Venn Life Sciences Share Discussion Threads

[timbo003] 25/9/2016 19:01

Venn are doing a short presentation/Investor evening on Wednesday 28th starting late afternoon/early evening near Bank Station (organised by their PR agency), I suggest you contact Walbrook if you want to go along (You will get fed and watered!)

[mickharkins1] 25/9/2016 12:09

Hi Adam - I'm no expert but my understanding is that the company perform a large number of clinical trials for clients.

I would assume these trials will have material/supplies costs and potentially even headcount costs - I do know of the operations of one R&D lab, which uses a lot of temporary headcount, to give them flexibility to manage the peaks and troughs in workload.

This would also seem to be borne out by the description in the accounts of 'Direct Project Costs' imo.

Cheers,
Mick

[adamb1978] 25/9/2016 09:43

Hi Mick
Given the nature of their business and looking just at CRO, aren't all the costs fixed?
Adam

[adamb1978] 25/9/2016 09:42

Have been through these for the first time over the last couple days and it feels as though Innovenn is effectively coming for free given that the CRO business more than justifies the share price on its own. Does anyone have a view on what Innovenn might be worth on a stand-alone basis if sold or spun-off?
Thanks

Adam

[mickharkins1] 25/9/2016 08:54

harry - thanks but the note to the account does not really help in determining which costs are variable and which are fixed.

[cocker] 24/9/2016 16:22

Wednesday should bring an update on Innovenn which was due over a month ago & I would be disappointed if we hear nothing. More importantly Venn is reporting good news with progress every time a rns is released. Sooner or later this will be re-rated big time.

[mulligut] 24/9/2016 13:19

What is also important to note is that their growth by M&A has created a reduction as a percentage of management as synergies kick in on management overhead. A couple of similar acquisitions that are accreditive will reduce them further. The model of CRO is about numbers of trials and the personnel on the ground. Management costs should remain the same, or at worst apprecaiting as a smaller percentage of the overall increase of revenues on each acquisition.

[harry vederci] 24/9/2016 11:47

see annual report note 6 Expenses - analysis by nature


Employee benefit expense (note 10)
Depreciation and amortisation
Transaction costs relating to business combinations and acquisitions (note 7)
Foreign exchange (gains)
Operating lease payments

Other expenses = €5.014m variables?

[mickharkins1] 24/9/2016 03:59

Having a look at VENN and am very impressed with the revenue growth. The big question mark for me is on operating margins - in the accounts, they lump Direct Project costs with Admin. Expenses, which is pretty unhelpful, as I assume Project costs are largely variable while Admin. Expenses are largely fixed.

Anyone have any ideas as to the split between the two (in the year to 2015, revenue was EUR 11.5 mio while Project Costs and Admin. Expenses were EUR 11.9 mio) or the margin percent? I see there is a breakdown of expense type in the notes to the accounts but doesn't really help determine the fixed v variable portion.

[glasshalfull] 23/9/2016 15:37

Perhaps someone's been buying 50k chunks InvestorDave
;-)

Kind regards,
GHF

[investordave] 23/9/2016 10:53

Someone seems to be offloading shares in chunks of 50,000 over the past few days. More fool them.

[mulligut] 23/9/2016 07:13

Is that what you call Premature Executivation?

[robbiereliable] 23/9/2016 06:58

"Mary Blake Sheahan, aged 44, is a dedicated senior leader with over 20 years' experience, at Executive Committee level of a multinational publicly listed biopharmaceutical company."Can anyone confirm whether the statement is correct, or is a slight elaboration? This would mean Miss Sheehan was 24 when she became an executive.

[cocker] 22/9/2016 09:57

Agree. As long as she delivers as to many of these aim companies waste money in the hope of bringing something to the table

[rivaldo] 22/9/2016 08:08

Impressive new NED appointment - ex-Perrigo and Elan senior VP should bring in lots of contacts and potential new business:

[investordave] 15/9/2016 21:32

Some healthy looking buys today although only a small tick up in the share price Something brewing perhaps?

[rivaldo] 15/9/2016 15:43

Looks like a tick up caused by a nice 75k buy at 28.6p.

[mulligut] 13/9/2016 09:43

Okay well that was the next announcement.... So much for my predictive capabilities. I would hope that the next announcement would be more M&A activity or contracts which would push it past the 30p mark.

[rivaldo] 13/9/2016 08:30

Yep, not only an impressive appointment - with the stress on the M&A aspect - but also good to see TR splitting the CEO and Chairman roles, which should please VENN's institutional shareholders.

[battlebus2] 13/9/2016 07:42

Director appointment, brings a wealth of experience including M&A.

[investordave] 07/9/2016 19:30

Let's hope so.

[mulligut] 07/9/2016 19:11

The next announcement may well drive it past the 30p mark.

[yump] 07/9/2016 18:40

Groundhog Day !

[mulligut] 07/9/2016 17:27

InvestorDave. I can't say that the move is significant considering the trend. Always good to have some liquidity to ensure a strong foundation to that trend. Some close out their profits and others joint the upward growth movement. All good and I expect there may well be some contract or M&A news as these things seem to be a regular occurrence, always providing positive momentum to the share price.

[investordave] 07/9/2016 16:09

Another significant fall in the share price today despite one 10K buy shown? Must be some large sells that have gone through, which will be shown after hours. Why sell now? Whoever it is must be v shortsighted given the massive potential here.